CRAM-A indicates IFN-γ-associated inflammatory response in breast cancer

Molecular Immunology

Volumn 68, Issue 2, 2015, Pages 692-698

  Sarmadi, Parisa ^a   Tunali, Gurcan ^a   Esendagli Yilmaz, Guldal ^b   Yilmaz, Kerim Bora ^c   Esendagli, Gunes ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Atypical chemokine receptor; Breast cancer; CCRL2; Decoy receptor; Immune response; Inflammation

Indexed keywords

BIOLOGICAL MARKER; CHEMERIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCRL2; CHEMOKINE RECEPTOR ON ACTIVATED MACROPHAGES A; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MESSENGER RNA; PROTEIN; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CCRL2 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL INFILTRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; TUMOR CELL LINE;

BIOMARKERS, TUMOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON-GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CCR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84949216400     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.10.019     Document Type: Article

References (23)

1. Bachelerie F., Graham G.J., Locati M., Mantovani A., Murphy P.M., Nibbs R., Rot A., Sozzani S., Thelen M. New nomenclature for atypical chemokine receptors. Nat. Immunol. 2014, 15:207-208.
2. Camp B.J., Dyhrman S.T., Memoli V.A., Mott L.A., Barth R.J. In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann. Surg. Oncol. 1996, 3:176-184.
3. Catusse J., Leick M., Groch M., Clark D.J., Buchner M.V., Zirlik K., Burger M. Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia. Mol. Cancer 2010, 9:297.
4. Filgueira L., Zuber M., Juretic A., Lüscher U., Caetano V., Harder F., Garotta G., Heberer M., Spagnoli G.C. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes. Cell Immunol. 1993, 150:205-218.
5. Forster R., Sozzani S. Emerging aspects of leukocyte migration. Eur. J. Immunol. 2013, 43:1404-1406.
6. Galligan C.L., Matsuyama W., Matsukawa A., Mizuta H., Hodge D.R., Howard O.M., Yoshimura T. Up-regulated expression and activation of the orphan chemokine receptor, CCRL2, in rheumatoid arthritis. Arthritis Rheum. 2004, 50:1806-1814.
7. Hartmann T.N., Leick M., Ewers S., Diefenbacher A., Schraufstatter I., Honczarenko M., Burger M. Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner. Immunology 2008, 125:252-262.
8. Hillinger S., Yang S.C., Zhu L., Huang M., Duckett R., Atianzar K., Batra R.K., Strieter R.M., Dubinett S.M., Sharma S. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J. Immunol. 2003, 171:6457-6465.
9. Hou T., Liang D., Yang D., He J., Huang Y., Zhang Y. High expression of CRAM correlates with poor prognosis in patients with cervical carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7:1060-1068.
10. Karasar P., Esendagli G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res. Treat. 2014, 145:605-614.
11. Leick M., Catusse J., Follo M., Nibbs R.J., Hartmann T.N., Veelken H., Burger M. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 2010, 129:536-546.
12. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.M. CCR5 is characteristic of Th1 lymphocytes. Nature 1998, 391:344-345.
13. Man Y.G., Stojadinovic A., Mason J., Avital I., Bilchik A., Bruecher B., Protic M., Nissan A., Izadjoo M., Zhang X., Jewett A. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J. Cancer 2013, 4:84-95.
14. Mantovani A., Garlanda C., Locati M., Rodriguez T.V., Feo S.G., Savino B., Vecchi A. Regulatory pathways in inflammation. Autoimmun. Rev. 2007, 7:8-11.
15. Migeotte I., Franssen J.D., Goriely S., Willems F., Parmentier M. Distribution and regulation of expression of the putative human chemokine receptor HCR in leukocyte populations. Eur. J. Immunol. 2002, 32:494-501.
16. Monnier J., Lewén S., O'Hara E., Huang K., Tu H., Butcher E.C., Zabel B.A. Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J. Immunol. 2012, 189:956-967.
17. Nathan C. Points of control in inflammation. Nature 2002, 420:846-852.
18. Nibbs R.J., Graham G.J. Immune regulation by atypical chemokine receptors. Nat. Rev. Immunol. 2013, 13:815-829.
19. Patel L., Charlton S.J., Chambers J.K., Macphee C.H. Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine 2001, 14:27-36.
20. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
21. Yin F., Xu Z., Wang Z., Yao H., Shen Z., Yu F., Tang Y., Fu D., Lin S., Lu G., Kung H.F., Poon W.S., Huang Y., Lin M.C. Elevated chemokine CC-motif receptor-like 2 (CCRL2) promotes cell migration and invasion in glioblastoma. Biochem. Biophys. Res. Commun. 2012, 429:168-172.
22. Yoshimura T., Oppenheim J.J. Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2) two multifunctional receptors with unusual properties. Exp. Cell Res. 2011, 317:674-684.
23. Zabel B.A., Nakae S., Zuniga L., Kim J.Y., Ohyama T., Alt C., Pan J., Suto H., Soler D., Allen S.J., Handel T.M., Song C.H., Galli S.J., Butcher E.C. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J. Exp. Med. 2008, 205:2207-2220.